who shouldn't take glp 1 should not a The promise and peril of GLP-1 agonists: What Researchers find GLP-1 medications safe

However, the mechanism is plausible

With respect to the primary endpoint of A1C reduction from baseline, dulaglutide 4.5 mg was superior to the 1.5 mg dose at Week 36 under the treatment regimen estimand (mean change from baseline [mean baseline 8.6%]: dulaglutide 1.5 mg -1.54%, dulaglutide 4.5 mg -1.77%

The dose is dependent on how well you tolerate the medication

Despite these findings suggesting a minimal direct influence of depression on glycemic control, this condition may still significantly heighten the risk of severe complications in diabetes [14], emphasizing the necessity for comprehensive management approaches that address both psychological and physiological aspects of diabetes care

Notably, these benefits were achieved without undesirable estrogenic effects on the uterus

however, in inflammatory disease states, particularly when intestinal barrier integrity and function may be compromised, LPS can enter the circulation, where it can activate TLR4 on inflammatory cells and trigger a systemic inflammatory response